Literature DB >> 2136810

Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion.

P A Reece1, I N Olver, R G Morris, J F Bishop, T W Guentert, H S Hill, B L Hillcoat.   

Abstract

Doxifluridine (5'-deoxy-5-fluorouridine, 5'-dFUR) metabolism has been reported to be saturable and associated with a fall in clearance of the drug as the dose is increased. The aim of the present study was to determine the disposition of 5'-dFUR and 5-fluorouracil (5-FU) when 5'-dFUR was given as a 5-day infusion, with the infusion rate increased stepwise every 24 h. Measurement of plasma and urinary levels of 5'-dFUR and 5-FU at steady state for each infusion rate enabled the estimation of 5'-dFUR renal (ClR) and nonrenal (ClNR) clearance and 5-FU renal clearance. A total of 28 patients with histologically proven malignancy received 5-day courses of 5'-dFUR ranging in dose from 3.75 to 20 g/m2 per 120 h. The lowest dose given over 24 h was 0.25 g/m2, and the highest was 5 g/m2. Steady-state plasma levels of 5'-dFUR ranged from 167 to 6,519 ng/ml. At these plasma levels there was no evidence of significant saturation of 5'-dFUR metabolism; steady-state plasma levels of 5'-dFUR increased approximately linearly with dose, and nonrenal clearance did not change significantly with dose. There was also no evidence of nonlinearity in 5'-dFUR renal clearance. The mean (+/- SD) ClR of 5'-dFUR was 108.9 +/- 53.6 ml/min per m2 (range, 45.7-210 ml/min per m2), and the ClNR was 728 +/- 181 ml/min per m2 (range, 444-1,119 ml/min per m2). Renal clearance comprised 13% of the total 5'-dFUR clearance. The mean renal clearance of 5-FU was 100.8 +/- 48.6 ml/min per m2 (range, 23.5-198 ml/min per m2). There was considerable interpatient variability in 5'-dFUR renal and nonrenal clearance, even at the same dose level. We concluded that the administration of 5'-dFUR by the infusion method described avoided the saturation of nonrenal elimination processes reported to occur with shorter infusion schedules.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2136810     DOI: 10.1007/bf00684885

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  The in vitro stability of doxifluridine in whole blood and plasma.

Authors:  L J Schaaf; B R Dobbs; I R Edwards; D G Perrier
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.

Authors:  A Kono; Y Hara; S Sugata; Y Karube; Y Matsushima; H Ishitsuka
Journal:  Chem Pharm Bull (Tokyo)       Date:  1983-01       Impact factor: 1.645

3.  Tumor inhibitory effects of a new fluorouracil derivative: 5'-deoxy-5-fluorouridine.

Authors:  W Bollag; H R Hartmann
Journal:  Eur J Cancer       Date:  1980-04       Impact factor: 9.162

4.  Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.

Authors:  R D Armstrong; R B Diasio
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

5.  Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine.

Authors:  H Ishitsuka; M Miwa; K Takemoto; K Fukuoka; A Itoga; H B Maruyama
Journal:  Gan       Date:  1980-02

6.  Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer.

Authors:  E A de Bruijn; A T van Oosterom; U R Tjaden; H J Reeuwijk; H M Pinedo
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

7.  5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.

Authors:  R D Armstrong; E Cadman
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

8.  Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats.

Authors:  J L Au; J S Walker; Y Rustum
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

9.  [5'-deoxy-5-fluoruridine, a new antineoplastic pyrimidine antimetabolite].

Authors:  H R Hartmann; W Bollag
Journal:  Schweiz Med Wochenschr       Date:  1980-07-08

10.  The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.

Authors:  L J Schaaf; B R Dobbs; I R Edwards; D G Perrier
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.